NET PROFIT FORECAST: Net profit is expected to rise to 1.67 billion pounds from 1.05 billion pounds, according to a consensus provided by the company. London-listed shares in GSK are up 4.1% since the ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a ...

British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales. The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk.

In GSK’s case, analysts forecast that its earnings will increase an extremely robust 18.3% a year to end-2027. Its 2024 results certainly showed a strong foundation for such growth, in my view. Sales ...